Objective: Our aim was to evaluate the contribution of flow cytometry (FC) analysis in patients with a histopathological diagnosis of mantle cell lymphoma (MCL) and to develop a reliable scoring system.Materials and Methods: We assessed the results of FC analysis in peripheral blood or bone marrow samples of 36 patients diagnosed with MCL by histopathological evaluation. Multivariate analysis identified 5 variables associated with MCL: CD23 negativity, CD5/19 common positivity, CD20/22 common bright positivity, FMC7 positivity, and clonal sIg bright positivity. A 5-point scoring system was devised using these parameters.Results: Twenty-five patients (69.4%) scored 5 points, 8 (22.2%) scored 4 points, and 3 (8.4%) scored 3 points. The diagnosis of MCL was confirmed by FC immunophenotyping in 91.6% of the patients.Conclusion: Our results suggest that a quintet diagnostic scoring system, which is considered to be reliable in the diagnosis of MCL, could make a substantial contribution to diagnosis and should be more widely introduced in practice.
Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houli- han A, Que TH, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8(10): 1640-5.
Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu- Ankomah KA, et al. Improvement of the chronic lymphocytic leuke- mia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997; 108(4): 378-82.
DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998; 25(1): 6-10.
Deneys V, Michaux L, Leveugle P, Mazzon AM, Gillis E, Ferrant A, et al. Atypical lymphocytic leukemia and mantle cell lymphoma immu- nologically very close: flow cytometric distinction by the use of CD20 and CD54 expression. Leukemia 2001; 15(9): 1458-65. [CrossRef]
Schlette E, Fu K, Medeiros LJ. CD23 expression in mantle cell lym- phoma: clinicopathologic features of 18 cases. Am J Clin Pathol 2003; 120(5): 760-6. [CrossRef]
Gong JZ, Lagoo AS, Peters D, Horvatinovich J, Benz P, Buckley PJ. Value of CD23 determination by flow cytometry in differentiating man- tle cell lymphoma from chronic lymphocytic leukemia/small lympho- cytic lymphoma. Am J Clin Pathol 2001; 116(6): 893-7. [CrossRef]
Kelemen K, Peterson LC, Helenowski I, Goolsby CL, Jovanovic B, Miyata S, et al. CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- dis- ease. Am J Clin Pathol 2008; 130(2): 166-77. [CrossRef]
Ho AK, Hill S, Preobrazhensky SN, Miller ME, Chen Z, Bahler DW. Small B-cell neoplasms with typical mantle cell lymphoma immuno- phenotypes often include chronic lymphocytic leukemias. Am J Clin Pathol 2009; 131(1): 27-32. [CrossRef]
Medd PG, Clark N, Leyden K, Turner S, Strefford JA, Butler C, et al. A novel scoring system combining expression of CD23, CD20, and CD38 with platelet count predicts for the presence of the t(11;14) translocation of mantle cell lymphoma. Cytometry B Clin Cytom 2011; 80(4): 230-7. [CrossRef]
Juncà J, Ruiz-Xivillé N, Granada I, Rodríguez-Hernández I, Navarro JT, Mate JL, et al. Scoring systems in mantle cell lymphoma: a critical point of view. Cytometry B Clin Cytom 2012; 82(2): 120-2. [CrossRef]
Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51(5): 364-9. [CrossRef]
Hoeller S, Zhou Y, Kanagal-Shamanna R, Xu-Monette ZY, Hoehn D, Bihl M, et al. Composite mantle cell lymphoma and chronic lympho- cytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol 2013; 44(1): 110-21. [CrossRef]
Choukri M, Taheri H, Seddik R, Benkirane S, Hamama A, Masrar A, et al. Mantle cell lymphoma diagnosis. Ann Biol Clin 2013; 71(1): 107-12.
Craig FE, Foon KA. Flow cytometric immunophenotyping for hema- tologic neoplasms. Blood 2008; 111(8): 3941-67. [CrossRef]
Liu W, Medeiros LJ, Lin P, Romaguera JE, Wang SA, Jorgensen JL. Usefulness of flow cytometric immunophenotyping for bone marrow staging in patients with mantle cell lymphoma after therapy. Am J Clin Pathol 2012; 137(4): 634-40. [CrossRef]
Matutes E, Parry-Jones N, Brito-Babapulle V, Wotherspoon A, Morilla R, Atkinson S, et al. The leukemic presentation of mantle-cell lym- phoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma 2004; 45(10): 2007-15. [CrossRef]
Gao J, Peterson L, Nelson B, Goolsby C, Chen YH. Immunophe- notypic variations in mantle cell lymphoma. Am J Clin Pathol 2009; 132(5): 699-706. [CrossRef]
Liu Z, Dong HY, Gorczyca W, Tsang P, Cohen P, Stephenson CF, et al. CD5- mantle cell lymphoma. Am J Clin Pathol 2002; 118(2): 216- 24. [CrossRef]
Bigoni R, Negrini M, Veronese ML, Cuneo A, Castoldi GL, Croce CM. Characterization of t(11;14) translocation in mantle cell lym- phoma by fluorescent in situ hybridization. Oncogene 1996; 13(4): 797-802.
Sun T, Nordberg ML, Cotelingam JD, Veillon DM, Ryder J. Fluores- cence in situ hybridization: Method of choice for a definitive diagnosis of mantle cell lymphoma. Am J Hematol 2003; 74(1): 78-84. [CrossRef]
Belaud-Rotureau MA, Parrens M, Dubus P, Garroste JC, de Mascarel A, Merlio JP. A comparative analysis of FISH, RT-PCR, PCR, and im- munohistochemistry for the diagnosis of mantle cell lymphomas. Mod Pathol 2002; 15(5): 517-25. [CrossRef]
Li JY, Gaillard F, Moreau A, Harousseau JL, Laboisse C, Milpied N, et al. Detection of translocation t(11;14) (q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 1999; 154(5): 1449-52. [CrossRef]